Aptevo Therapeutics Inc (APVO) Cotización

$APVO: Mega POP in PM... now $6 !!!!!!!

Wow............... was just $3 minutes ago.

And there she goesssssssssssssssssss


Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML


Aptevo Therapeutics (NASDAQ:APVO) reported promising clinical data from its Phase 1b/2 RAINIER trial evaluating mipletamig, a CD123 x CD3 bispecific antibody, combined with venetoclax and azacitidine for frontline AML patients unfit for intensive chemotherapy. The triplet therapy achieved an impressive 85% remission rate across two trials, significantly outperforming competitor studies. Notable safety outcomes include no cytokine release syndrome (CRS) in cohorts 1 and 2. Three patients with poor prognosis achieved complete remission, with one successfully proceeding to transplant. The trial's Cohort 3 is nearing full enrollment at the highest dose level. Mipletamig's unique CRIS-7 binding domain engineering strategy demonstrates potential in mitigating cytokine-related toxicity while maintaining anti-cancer activity.


GO $APVO

APVO..............................................https://stockcharts.com/h-sc/ui?s=APVO&p=W&b=5&g=0&id=p86431144783

APVO.....................https://stockcharts.com/h-sc/ui?s=APVO&p=W&b=5&g=0&id=p86431144783

Zero borrow/640%fee!(no rebate now,was 635%,been waiting for this) offering closed yesterday,3m float from r/s,cancer cure news before offering.

apvo.......................................................................p/m

APVO, new 52 week low

APVO.............................................................p/m

APVO...........................................................a/h

$APVO: BOostinggggggggg.. now $2.59

And HALTED.

Wasssupppppppppppppppppppppppppppppppp


GO $APVO

soon to be a phase 2/3 company. pick any aml cancer biotech at that stage and their valuation is at least 30M. we will see 6-8x increase from here

Valuation will follow. "100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial"

Don’t worry brother shorts in big trouble https://franknez.com/short-sellers-are-now-under-federal-investigation-for-collusion/

APVO: Hey, Colonel M-l-K, Dude, always first check with my own online 'BROKER' (see below) before you invest in ANY Wall Street gambling chips, Homeboy!!!!

APVO: Indeed, Bro!!! (However, see selfie film-clip of ME, below --- doin' a 'WILL SMITH' on my own FACE --- for buying this crap in the first place!!!)

With this magnitude news you would suppose to be celebrating
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Two of three patients achieved both complete remission and MRD-negative status

High response rates observed in earlier studies continue in ongoing mipletamig trial

Cohort 2 enrollment commencing

SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual disease (MRD)-negative status (100% elimination of cancer cells). The results build on data from the prior trial, in which 100% of frontline patients also achieved remission. *(Remission = complete remission (CR) and, complete remission with blood markers that have not yet recovered (CRi).

"We are very excited by these Cohort 1 results as they add to an already compelling story that highlights mipletamig's potential to elevate the frontline AML treatment paradigm. We now have a 100% rate of remission in Cohort 1 of RAINIER. We saw a 100% rate of remission in frontline patients treated with the combination in our completed dose expansion trial. Remarkably, 86% of patients across both trials went into remission within 30 days of receiving their first treatment," said Marvin White, President and CEO of Aptevo. "It's also important to note that mipletamig continues to demonstrate a favorable safety and tolerability profile, reinforcing its potential as a transformative addition to the standard of care combination. Cohort 2 enrollment is commencing, marking the next step in the study. We look forward to sharing new results as they become available."

Mipletamig, a CD3 x CD123 bispecific antibody, is being investigated as frontline therapy in combination with venetoclax and azacitidine, a current standard of care for AML. These latest results further reinforce mipletamig's potential as a transformative treatment, supported by impressive efficacy, safety, and tolerability data from two prior clinical trials involving 90 patients.

"Achieving remission in all three Cohort 1 patients is highly encouraging, particularly when viewed alongside prior trial results. Notably, two of these three patients achieved MRD-negative status, a critical outcome indicating that even the most sensitive diagnostic methods detect no remaining cancer cells. This result is strongly associated with longer-lasting remissions and improved survival rates," said Dirk Huebner, MD, Chief Medical Officer at Aptevo. "What makes these outcomes even more compelling is that one of the MRD-negative patients had a TP53 mutation, a subgroup known for its poor prognosis due to chemotherapy resistance, genetic instability, and overall treatment challenges. This growing body of data underscores mipletamig's potential to address some of the most difficult hurdles in AML treatment, delivering deep and durable responses for patients with the greatest need."

About RAINIER

RAINIER, a frontline AML study, is a Phase 1b/2 dose optimization, multi-center, multi-cohort, open label study of up to 39 patients who are being treated across five dose levels ranging from 9 mcg - 140 mcg in combination with venetoclax and azacitidine (ven/aza). Subjects will be adults aged 18 or older, newly diagnosed with AML who are not eligible for intensive induction chemotherapy. Phase 1b consists of 28-day cycles of treatment in five sequential cohorts. Aptevo has partnered with Prometrika (https://www.prometrika.com/), a premier contract research organization for the trial. RAINIER will be conducted in two parts. First, a Phase 1b dose optimization study in frontline AML patients followed by a Phase 2 study.

About Mipletamig

Aptevo's wholly owned lead proprietary drug candidate, mipletamig, targeting AML, MDS and other leukemias, is differentiated by design to redirect the immune system of the patient to destroy leukemic cells and leukemic stem cells expressing the target antigen CD123, which is a compelling target for AML due to its overexpression on leukemic stem cells and AML blasts. This antibody-like recombinant protein therapeutic is designed to engage both leukemic cells and T cells of the immune system and bring them closely together to trigger the destruction of leukemic cells. Mipletamig is purposefully designed to reduce the likelihood and severity of CRS by use of a unique CD3 derived from CRIS-7 vs. the CD3 used by other competitors. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. Mipletamig has been evaluated in 90 patients over two trials to date. RAINIER, Aptevo's Phase 1b/2 frontline AML program, was initiated in 3Q24.

About Aptevo Therapeutics

Aptevo Therapeutics Inc. (Nasdaq:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard of care venetoclax + azacitidine. Mipletamig has orphan status for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist that is only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. Aptevo has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR® and ADAPTIR-FLEX®. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax + azacitidine on a targeted patient population will continue to show remissions, let alone at a rate of 100%, whether Aptevo's final remission data or trial results will vary from its earlier assessment, whether Aptevo's strategy will translate into an improved overall survival in AML, especially among patient subgroups with poor prognosis, whether further study of ALG.APV-527 across multiple tumor types will continue to show clinical benefit, the possibility and timing of future preliminary or interim data readouts for ALG.APV-527, statements related to the progress of and enthusiasm for Aptevo's clinical programs, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.

There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine, war between Israel and Hamas, and macroeconomic conditions such as economic uncertainty, rising inflation and interest rates, continued market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.

Live the dream with the nobel prize criminal winners their scam machine designed to rape investors while they fill up their pockets in bed with the short criminals

APVO RNAZ the biggest piece of shit scams of the nobel prize scientific community

These nobel prize scientists are all the legal criminals of the nasdaq hiding under the look forward statements while they fill up their pocket and screw all shareholders in bed with the shorts just like RNAZ

APVO: I had a REALLY bad day yesterday, Bro!!!

How does it feel getting screwed by the Nobel prize scientific community? These rat bastards in management screwed everyone and everything all their careers

One just has to LAUGH at this Wall Street CHIT!!

Wow, very impressive,

APVO; Heck, it just hit circa 7% GREEN in the Post-Market, Dude!! (See my 'BROKER', below, as he is workin'-on WHERE this lame duck might go NEXT!!)

APVO Run up that donkey

APVO: And those nasty, 'Dirty-Slim-Balls', too!!!

That damn 'coulda-woulda-shoulda' syndrome!! I HATE when that happens!!

Or coulda woulda just shorted it shares were available earlier a little more expensive 

APVO: INDEED!!! (Glad I didn't toss the 'FARM' at this crap!!)

Hell yes let’s ride the donkey!!!!

Will management funnel all the money they raised strait in their pockets and fuck all shareholders up the ass just like Rnaz

It’s been assessed that management are dirty slim balls of the nasdaq scammers likE RNAZ

What’s the float with this piece of garbage

Management in bed with the shorts since inception
https://newsable.asianetnews.com/amp/markets/aptevo-therapeutics-stock-draws-retail-attention-after-leukemia-trial-data-retail-extremely-bullish-soe8pm

It's a shame to get stuck but in penny land you imo you have to be a quick flipper and if you want to take extra risk only keep some of the gains from the quick flip running some more especially on these super tiny floaters where they have a much higher chance of offerings. 

APVO Is just another scientific scam from the nobel prize winners , Just like the peddlers at RNAZ

https://www.investing.com/news/company-news/aptevo-reports-full-remission-in-aml-trial-93CH-3769094

APVO: Nope!! This firm needs only THEMSELVES to screw their shareholders!! And, of course, a cheap PR firm like "Accesswire" to publish their next CANCER CURE baloney!!!

APVO: Like I noted, hours ago I got an urgent iHub PRIVATE MESSAGE, warning me about this, and from an iHuber I have never before encountered. He sent me the entire detailed insider DOCUMENTS, which described APVO's clever WARRANTS DUMPING routine of today. But I disregarded said warning. (And I myself just now DD'd the "AUTHORIZED SHARES" of this firm; to wit, 500,000,000+!!!! So, they have plenty more to DUMP into the Market, whenever they launch yet ANOTHER bogus PR about a Cancer cure!!!)

APVO Is the same scam as RNAZ

Is management in bed with shorts to destroy all shareholders

These guys are part of the nobel prize micro rnaz clinical trial scam

APVO: That's why NO OTHER media firms --- except for "Accesswire" --- would even touch APVO's purported "Cancer" cure news tpday!!!

APVO: The FIRM itself dumped hugely 25-minutes ago!!! Just as devastating as those firms that launch monster NEWS, and then do a big PUBLIC OFFERING later in the day!!! Same effect!!! (I was warned about this in an iHub PRIVATE email hours ago, Bro!!!)
https://finance.yahoo.com/news/aptevo-therapeutics-announces-exercise-warrants-175000415.html

Are these scam artist part of the nobel prize micro rna hoax

APVO: Huge dump!!! (Likely due to the extremely SMALL number of patients and, as such, NOT considered to be a legitimate STUDY.)

APVO Is another disgrace like RNAZ

Pharma whales lurking waters

Accumulation brothe… Fssten up$$$

APVO: Your iHub motto is, "No time to dream, time to achieve". (Below is a great song in that regard, Homeboy!!!)

Shorts are painting fake walls in panic for their short asses about to explode in their faces

Hell yes brother🚀🚀🚀🚀

APVO: My "BROKER' just sent me your instructions, Lord King, Dude!!! (See her below, Bro!!!)